Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor

Author： Moore K.H.P. Cass L.M. Dallow N. Hardman T.C. Jones A. Boyce M. Prince W.T.

Publisher： Springer Publishing Company

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.56, Iss.11, 2001-01, pp. : 805-811

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacokinetics of Single Oral Doses of Apricitabine, a Novel Deoxycytidine Analogue Reverse Transcriptase Inhibitor, in Healthy Volunteers

By Holdich Tom

Clinical Drug Investigation, Vol. 26, Iss. 5, 2006-01 ,pp. : 279-286

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

By Smith P.F.

Clinical Pharmacokinetics, Vol. 40, Iss. 12, 2001-01 ,pp. : 893-905

Adis International

Access to resources Recommend Favorite

Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens

By Taneja Charu Juday Timothy Gertzog Larry Edelsberg John Correll Todd Hebden Tony Oster Gerry

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 15, 2012-10 ,pp. : 2111-2118

Informa Healthcare

Access to resources Recommend Favorite

Should Non-Nucleoside Reverse Transcriptase Inhibitors be Combined?

By Kappelhoff Bregt S. Huitema Alwin D.R. Beijnen Jos H.

Drugs in R&D, Vol. 6, Iss. 2, 2005-01 ,pp. : 61-69

Adis International

Access to resources Recommend Favorite

Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

By Cahn Pedro

Clinical Drug Investigation, Vol. 28, Iss. 2, 2008-01 ,pp. : 129-138

Adis International

Access to resources Recommend Favorite